This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Schmitt, G. J. E. Articles by Möller, H.-j. Search for Related Content PubMed PubMed Citation Articles by Schmitt, G. J. E. Articles by Möller, H.-j. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Nuclear Scans Psychotic Disorders Schizophrenia Social Bookmarking                         What's this?

Striatal dopamine D2 receptor binding of risperidone in schizophrenic patients as assessed by 123I-iodobenzamide SPECT: a comparative study with olanzapine

Departments of Psychiatry, Ludwig-Maximilians-University Munich, Germany

E. M. Meisenzahl

Department of Psychiatry, Ludwig-Maximilians-University Munich, Nübaumstrasse 7, 80336 München, Germany; emeisen{at}psy.med.uni-muenchen.de

S. Dresel

K. Tatsch

B. Rossmüller

Department of Nuclear Medicine, Ludwig-Maximilians-University Munich, Germany

T. Frodl

U. W. Preuss

Departments of Psychiatry, Ludwig-Maximilians-University Munich, Germany

K. Hahn

Departments of Nuclear Medicine, Ludwig-Maximilians-University Munich, Germany

H.-j. Möller

Departments of Psychiatry, Ludwig-Maximilians-University Munich, Germany

The aim of this investigation was to compare the degree of striatal dopamine-(D2) receptor blockade by two atypical antipsychotic drugs, risperidone and olanzapine. The percentage of D2 receptor occupancy during treatment was calculated by comparing the results of 123I-iodobenzamide SPECT with those from healthy control subjects. Twenty inpatients suffering from schizophrenia or schizoaffective psychosis according to DSM IV/ICD-10 criteria were treated with clinically recommended doses of risperidone and compared with 13 inpatients treated with up to 20 mg olanzapine. Neuroleptic dose and D2 receptor blockade correlated strongly for both risperidone (Pearson r = –0.86, p = 0.0001) and olanzapine (Pearson r = –0.77, p = 0.002). There was no significant difference between the D2 receptor occupancy of the two substances when given in the clinically recommended dose range (unpaired t-test, t= –0.112, p=0.911).

Key Words: atypical neuroleptics • dopamine D2 receptor • 123I IBZM • olanzapine • risperidone • SPECT

Journal of Psychopharmacology, Vol. 16, No. 3, 200-206 (2002)
DOI: 10.1177/026988110201600302


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Catafau, M. Penengo, G. Nucci, S. Bullich, I. Corripio, E. Parellada, C. Garcia-Ribera, R. Gomeni, E. Merlo-Pich, and Barcelona Clinical Imaging in Psychiatry Group Pharmacokinetics and time-course of D2 receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients J Psychopharmacol, November 1, 2008; 22(8): 882 - 894. [Abstract] [PDF]

				C. la Fougere, E. Meisenzahl, G. Schmitt, J. Stauss, T. Frodl, K. Tatsch, K. Hahn, H.-J. Moller, and S. Dresel D2 Receptor Occupancy During High- and Low-Dose Therapy with the Atypical Antipsychotic Amisulpride: A 123I-Iodobenzamide SPECT Study J. Nucl. Med., June 1, 2005; 46(6): 1028 - 1033. [Abstract] [Full Text] [PDF]

				R. M. Moresco, R. Cavallaro, C. Messa, D. Bravi, C. Gobbo, L. Galli, G. Lucignani, C. Colombo, G. Rizzo, I. Velona, et al. Cerebral D2 and 5-HT2 Receptor occupancy in Schizophrenic Patients Treated with Olanzapine Or Clozapine J Psychopharmacol, September 1, 2004; 18(3): 355 - 365. [Abstract] [PDF]